Register to attend a free NIH webinar. Attendees will learn about a new T-cell receptor (TCR) that targets CD22, being developed by the National Cancer Institute (NCI) as a cellular immunotherapy to treat lymphomas and leukemias. CD22 TCR-T cells clear leukemia at clinically relevant doses without causing systemic cytokine elevation.

The webinar will highlight:

• Novel CD22 specific TCR-T cells reducing tumor burden at clinically relevant doses

A new therapeutic method using these novel CD22 specific TCR-T cells that overcomes current treatment limitations for hematologic malignancies.